Platelets are the primary cellular determinants of haemostasis and pathological thrombus formation leading to myocardial infarction and stroke. Following vascular injury or atherosclerotic plaque rupture, platelets are recruited to sites of damage and undergo activation induced by a variety of soluble and/or insoluble agonists. Platelet activation is a multi-step process culminating in the formation of thrombi, which contribute to the haemostatic process. Zinc (Zn 2+ ) is acknowledged as an important signalling molecule in a diverse range of cellular systems, however there is limited understanding of the influence of Zn 2+ on platelet behaviour during thrombus formation. This review evaluates the contributions of exogenous and intracellular Zn 2+ to platelet function and assesses the potential pathophysiological implications of Zn 2+ signalling. We also provide a speculative assessment of the mechanisms by which platelets could respond to changes in extracellular and intracellular Zn 2+ concentration.
, supporting a role for this cation in the modulation of intracellular signalling pathways. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Although the involvement of Zn 2+ in haemostatic processes has been the subject of recent reviews, 21, 22 there is limited understanding of the contributions by Zn 2+ to platelet function during haemostasis and thrombosis. Here we consider the current understanding of Zn 2+ as an extracellular agonist and an intracellular signalling modulator in platelets. Given the limited information on this subject, we draw on Zn 2+ -responsive signalling pathways and cellular processes described in other cell types, and assess the mechanism(s) and/or machinery available for use by Zn 2+ in the context of platelet activation.
Platelet physiology
Platelets play a central role in haemostasis and inappropriate platelet activation is a major precipitating factor in cardiovascular disease. 23 Engagement of platelet surface receptors with thrombogenic extracellular matrix molecules (e.g. collagen and von Willebrand factor) or by soluble mediators (including ADP, ATP, thrombin and thromboxane A 2 ) leads to platelet activation, culminating in stable adhesion to the subendothelium and formation of thrombi. This is a highly dynamic process involving cytoskeletal rearrangements, granule release and increased affinity of integrins for their cognate ligands. 24 Activation is mediated by platelet membrane receptors, including tyrosine kinase-associated receptors (such as GpVI and CLEC-2, reviewed in ref. 25 ) and G-protein coupled receptors (GPCRs, reviewed in ref. 26 ). Elevation of intracellular Ca 2+ ([Ca 2+ ] i ), mediated by release from intracellular stores and influx through membrane ion channels is a hallmark of platelet activation (reviewed in ref. 27 ). The primary endpoint of platelet activation is high affinity binding of integrin a IIb b 3 to fibrinogen, leading to thrombus formation. 28 Conversion of fibrinogen to insoluble fibrin by thrombin, generated by the coagulation pathway, stabilises the thrombus leading to the cessation of bleeding. Chronic cardiovascular diseases narrow the arterial lumen, reducing blood flow and elevating local shear rates. Subsequent atherosclerotic plaque rupture exposes collagens which, in conjunction with elevated shear rates, increase the propensity for platelet activation. 23, 29, 30 Thrombus formation at these sites may lead to vessel occlusion or generate emboli, elevating the risk of myocardial infarctions and stroke.
Zn
2+ as a mediator of haemostasis
The first observations of a functional relationship between Zn
2+
and platelet activation were made in rats undergoing experimental Zn 2+ deficiency. These studies demonstrated that Zn 2+ -deficient rodents have an increased bleeding tendency, more difficult parturition and prolonged tail bleeding times. [31] [32] [33] [34] Consistent with a link between Zn 2+ status and platelet function, this bleeding diathesis has been reported in both male and female animals [31] [32] [33] and is phenotypically similar to that of aspirin treatment. 32 Interestingly, this phenomenon has also been reported in human subjects. TPEN inhibits platelet aggregation induced by conventional agonists including ADP, thrombin and PMA, although the effect seen with thrombin is restricted to low agonist concentrations. [60] [61] [62] TPEN also reduces thrombin-evoked [Ca 2+ ] i mobilisation, phosphatidylserine externalisation and phosphorylation of eIF2a. 63 In a physiological blood flow model, TPEN-treated platelets were unable to activate to a degree sufficient for generation of full thrombi. 62 Whether this effect is due to chelation of labile -binding proteins and anticoagulants. Zinc-induced platelet aggregation occurs within a physiologically-relevant timeframe, comparable to that of the conventional agonists ADP, collagen and thrombin. [60] [61] [62] Aggregation is biphasic and accompanied by a discernible shape change, 60, 64 indicating a role for secondary activation by soluble agonists and cytoskeletal rearrangements, respectively. Taken together, these features of Zn
-induced aggregation are reminiscent of those observed by others in response to other agonists, suggesting that Zn 2+ is a bona fide platelet agonist.
Whether Zn 2+ acts as a transmembrane signaller in a similar manner to that reported for synaptic transmission and insulin release, 3,65 or modulates extracellular receptor activity directly
has not yet been fully resolved. Platelet aggregation is mediated by integrin a IIb b 3 which, upon switching to its high affinity state, is able to bind to arginine-glycine-aspartate (RGD) motifs in proteins such as fibrinogen and von Willebrand factor facilitating platelet crosslinking. 23 Conversely, platelet agglutination occurs as a result of direct activation of adhesive receptors, without a requirement for intracellular signalling. 23 Integrins transduce signals in response to extracellular and intracellular cues via outside-in and inside-out signalling, respectively. Inside-out activation concerns cytosolic events that increase the affinity of the receptor for its ligand, whereas outside-in signalling coordinates cellular responses to ligand binding. 23 The nature of ion channels expressed on the platelet surface has been the subject of a recent review. 27 Here, we limit our discussion to ion channels/exchangers known to be expressed by platelets, which have shown Zn
-permeability in other cell types and may therefore contribute to Zn 2+ entry.
Glutamate receptor subunits 1-6 are expressed on platelet membranes and glutamate has previously been shown to mediate platelet activation through kainate and AMPA receptor activities. 79, 80 Platelets and megakaryocytes (platelet precursor cells) also express NMDA receptors. [80] [81] [82] [83] [84] Although unable to aggregate platelets directly, glutamate potentiates platelet responses to agonists including thrombin and thromboxane A 2 , indicating that these channels are functional during platelet activation. 80 Adu et al., demonstrated that whilst stimulation of platelets by 2.8 mg ml À1 collagen gave a partial aggregation, inclusion of 100 mM Zn 2+ in the suspension was potentiatory and resulted in full aggregation. 64 Similar results were observed using ADP as an agonist. The potentiating effect on ADP signalling is blocked following TPEN treatment. Low concentrations of Zn 2+ also potentiate ADP-mediated a-granule release, measured using platelet-released b thromboglobulin. 60 More recently, we have demonstrated that this potentiating effect is evident when platelets are pre-incubated with 30 mM Zn 2+ and challenged with CRP-XL (collagen-related peptide, a GpVI ligand), thrombin, U46619 or adrenaline. 62 Thus, low [Zn 2+ ] o potentiates agonistevoked platelet activation, supporting the concept of a physiological role for Zn 2+ in platelet thrombus formation.
Mechanism of action of Zn 2+ in platelet activation
The mechanism by which Zn 2+ induces platelet aggregation has been studied by pharmacological targeting of various aspects of platelet signalling. 
